Gossamer Bio(US:GOSS)2025-03-13 20:02Financial Performance - Cash, cash equivalents, and marketable securities totaled $294.5 million as of December 31, 2024[11] - Net loss for Q4 2024 was $33.0 million, or $0.15 per share, compared to a net loss of $48.1 million, or $0.21 per share, for the same period in 2023[10] - Total revenue for the full year ended December 31, 2024, was $114.7 million, with $90.7 million from license sales and $24.0 million from contracts with collaborators[10] - The accumulated deficit as of December 31, 2024, was $1.27 billion, compared to $1.21 billion at the end of 2023[11] Research and Development - Research and Development (R&D) expenses for Q4 2024 were $36.1 million, up from $30.0 million in Q4 2023, while full-year R&D expenses were $138.5 million compared to $135.3 million in 2023[10] - A registrational Phase 3 clinical trial in PH-ILD is expected to commence in the second half of 2025[1] - The PROSERA Phase 3 study in PAH is on track for topline data readout in Q4 2025, with enrollment ongoing[1] - Seralutinib received Orphan Drug Designation for PAH in Japan, which may support a marketing application pending clinical trial results[8] General and Administrative Expenses - General and Administrative (G&A) expenses for Q4 2024 were $9.4 million, slightly up from $9.1 million in Q4 2023, with full-year G&A expenses at $36.1 million compared to $38.5 million in 2023[10] Cash Flow and Funding - The company expects its current cash and marketable securities to fund operations into the first half of 2027[8]